Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Asahi Kasei’s Recomodulin Enters US-Japan PI Study for Chemotherapy-Induced Peripheral Neuropathy
March 29, 2022
- Yakult Honsha Files Blood Cancer Med Duvelisib in Japan
March 25, 2022
- Shionogi Seeks Japan Approval of Novel Antibiotic Cefiderocol
March 25, 2022
- Towa Wins Livalo Damage Suit; Kowa to Appeal Ruling
March 25, 2022
- Fujifilm to Snap Up US Recombinant Protein Manufacturer
March 24, 2022
- Ube Grants Global Rights for CDK7 Inhibitor to Kirilys
March 24, 2022
- Chugai to Scale Down Wholesale Promotion Spend as Portfolio Pivots to Specialty Care: CEO
March 24, 2022
- Lecanemab Scores Positive Results in PIIb Study: Eisai/Biogen
March 23, 2022
- Sales Reps’ Online Detailing Activities Log Double-Digit Rise MOM, YOY in January: Intage
March 23, 2022
- Vectibix/Chemo Extends OS in 1st Line Colorectal Cancer: Japan PIII
March 22, 2022
- Sanofi Files PD-1 Drug Cemiplimab for Cervical Cancer in Japan
March 22, 2022
- Generic Makers, PMDA Exploring GMP Inspection Methods for Overseas Sites; Onsite Checks Not Possible for 2 Years
March 18, 2022
- Chugai Aspires to Grow Beyond 1 Trillion Yen Company: CEO
March 18, 2022
- Biogen Unveils Peer-Reviewed Aduhelm Data 9 Months after FDA OK
March 18, 2022
- Kenei, Maruho Settle Healmild Dispute; Brand Name to Remain with Design Changes
March 18, 2022
- Kyorin Grants Chinese Rights for Lascufloxacin to Local Company
March 18, 2022
- Chugai, Alexion Settle Patent Suits over Ultomiris
March 18, 2022
- FDA Clears Shionogi’s COVID-19 Pill for Global PIII Study
March 17, 2022
- Aduhelm Deal Revised, Eisai Poised to Sharpen Focus on Lecanemab: CEO
March 17, 2022
- Biogen/Eisai Alzheimer’s Pact Amended to Switch Aducanumab Collab to Royalty Scheme
March 16, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…